Four fixed examples separate an organism name, a quantity declaration, a study preparation and a reported outcome. Read every source boundary with its record.
This reader explains published records and questions for qualified professionals. It does not identify a suitable product, assess medicine combinations, interpret personal symptoms, select a quantity or replace prescribed care. A probiotic marketed with GLP-1 wording is not a GLP-1 receptor agonist medicine. The examples do not establish product equivalence, a verified supplied lot or individual benefit. No information is entered, stored or sent by this fixed reader.
Four evidence records
Which organism is actually identified?
The published record
CoreAge names three organisms without strain codes. The pictured Pendulum panel gives two WB-STR codes but no code beside B. infantis. Culturelle names the GG strain.
What the source covers
The current product records establish what each seller declares. NIH explains the separate roles of genus, species and strain identifiers.
What remains unresolved
Similar species names do not establish shared strains, equivalent formulas or the same clinical result. Missing identifiers remain missing.
A question to take forward
For the manufacturer, which exact strain codes and finished preparation does the cited paper describe, and what documentation connects those details to the current product? A clinician or pharmacist can separately consider whether that research is relevant to an individual care question.
The current CoreAge record gives a 36 mg blend; Pendulum gives a combined 500 million AFU blend; Culturelle prints 40 mg and 10 billion CFUs for GG.
What the source covers
These are source declarations with different measurement labels. The public ISO abstract describes a defined flow-cytometry method within a dairy/probiotic scope, not the method used for these specific products.
What remains unresolved
No reviewed record provides an exchange rate among milligrams, AFU and CFU, or a validated cross-product potency comparison. A combined amount does not supply each organism’s amount.
A question to take forward
For the manufacturer or testing laboratory, what method, organisms and measurement time point does this declaration cover? A qualified care professional, rather than a conversion between label units, must address any personal question about use.
The 2020 WBF study tested separate formulations in 76 adults with type 2 diabetes over 12 weeks. WBF-011 contained five organisms plus inulin; the current Pendulum GLP-1 retail panel names three organisms plus inulin.
What the source covers
The primary paper supplies the study preparation, population and design. The current retail panel supplies a different product record. These sources can document that distinction without proving equal or unequal clinical performance.
What remains unresolved
Shared organism names do not establish that a result transfers between those preparations, to CoreAge, to Culturelle or to all people taking GLP-1 medicines.
A question to take forward
For the clinician or pharmacist, is there a published study of this exact preparation in a relevant population, and what outcome did it measure? The manufacturer can be asked for the publication and formula documentation without being treated as the person’s prescriber.
Pendulum describes six-week consumer-survey reports about cravings. The WBF randomized trial studied glucose-related outcomes in people with type 2 diabetes.
What the source covers
A survey records reported experience within its disclosed design. A randomized trial has its own comparison, preparation and measured endpoints. Neither becomes a trial of prescription GLP-1 treatment side effects merely through shared branding.
What remains unresolved
The two records do not answer the same question. Neither establishes personal suitability, a substitute for a prescription medicine or permission to overlook new symptoms.
A question to take forward
For the professional reviewing the claim, what was actually measured, in whom, against which comparison, and does that answer the clinical question? The seller can clarify its survey or citation, but a marketing response does not establish an individual benefit.